Soreide Law Group has been receiving calls from our clients who purchased MabVax Therapeutics Holdings, Inc. (MBVX) and experienced significant stock losses. Not only were the brokers from Laidlaw and Company offering this stock, but Laidlaw also served as the “Sole Placement Agent” for the offering. Securities that are newly issued are typically more volatile than the older more established companies, and if the investor was not looking to speculate, this could have been an unsuitable recommendation given to you by your broker from Laidlaw and Company.
According to Yahoo Finance, MabVax Therapeutics Holdings, Inc. (MBVX), is a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.
In June of 2013, MabVax Therapeutics Holdings, Inc. (MBVX) was trading around 261.33, and today it is trading at approximately 1.76. The 52-week change is -67.25%.
On Laidlaw and Company’s website, the following information on their company is given: ”Our team of bankers’ focus on the healthcare industry and the depth of their experience allows them to provide comprehensive knowledge of both the industry and the markets.”
If you’ve experienced significant investment losses in MabVax Therapeutics Holdings, Inc. (MBVX)due to the recommendations of a Laidlaw and Company securities broker, call Soreide Law Group for a no cost consultation with an experienced securities lawyer regarding the possible recovery of your financial losses through a FINRA arbitration at: 888-760-6552.
Soreide Law Group represents clients nationwide before FINRA. We operate on a contingency fee basis, no fee if no recovery.
FINRA barred securities broker Alan K. Ngo [CRD: 4273116, Freehold, New Jersey], given the publicly available information on Financial Industry Regulatory Authority (FINRA) BrokerCheck. Ngo worked for PFS Investments Inc. from January 2, 2003, to November 25, 2025. See below to learn more about Ngo’s disclosures. FINRA Sanctioned Ngo For Failing To Comply During Investigation […]
FINRA barred securities broker Kevin Christopher McCarthy [CRD: 1702715, Hialeah, Florida], and investors complained about him, based on public information found on Financial Industry Regulatory Authority (FINRA) BrokerCheck. McCarthy worked for Madison Avenue Securities LLC from December 4, 2007, to January 30, 2026. Investors are encouraged to continue reading to find out more about McCarthy’s […]
FINRA barred securities broker Mohammed Anayet Karim [CRD: 4419277, Lakeland, Florida], according to publicly available information on Financial Industry Regulatory Authority (FINRA) BrokerCheck. Karim worked for BB&T Securities LLC from September 24, 2018, to February 17, 2021, and Truist Investment Services Inc. from February 17, 2021, to August 8, 2025. See the following information to […]
Phone:
Fax: 1-954-760-6553
Email: info@securitieslawyer.com